A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer.

Among the T cells, CD4 + (42% vs 50%, p = 0.0237) and CD8 + (25% vs 30%, p = 0.09) T cells showed a trend towards increase, while double negative (CD4-CD8-) T cells (35% vs 22%, p = 0.0082) were significantly reduced in the treatment group (Fig. 6f ). 6TdG treatment resulted in significantly reduced expression of checkpoint receptors, PD-1 and Tim3, on CD8 + T cells (PD-1: 8.2% vs 3.5%, p = 0.0097; Tim3: 6.7% vs 3.2%, p = 0.0097) (Fig. 6f ).

also in 10,348 other papers